Product Details
| Product Name: Everolimus | CAS No.: 159351-69-6 |
| EC-No.: 621-003-9 | Min. Order: 1g |
| Purity: 99 | Supply Ability: 10kg |
| Release date: 2026/05/15 |
CAS: 159351-69-6
MF: C53H83NO14
MW: 958.22
EINECS: 621-003-9
Melting point NA
Boiling point 998.7±75.0 °C(Predicted)
density 1.18±0.1 g/cm3(Predicted)
Fp 2℃
storage temp. ?20°C
Everolimus (IX) (SDZ-RAD), was developed by Novartis as an immunosuppressant to be used in conjunction with cyclosporin in transplantation allograft rejection and was recently approved in the US in 2003. Another natural product that had been approved for use in transplantation is rapamycin (sirolimus) as an inejectable agent. In an attempt to develop an orally bioavailable immunosuppressant agent, many companies attempted modification of rapamycin itself.
Company Profile Introduction
You may like
-
CAS:314771-88-5
$1365.00
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-05 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-05 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-06-04 | ||
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2026-06-03 | ||
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $37.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
|
VIP1Y
|
Jinan Ruitong Biotech Co., Ltd.
|
2025-09-04 | ||
| $10.00 |
XI'AN TIANGUANGYUAN BIOTECH CO., LTD.
|
2024-09-18 |
- Since: 2018-09-06
- Address: B801, Jintai District, Baoji City, Shaanxi Province, China, Dongling Financial Plaza, Jintai Distric
13892490616
gksales1@gk-bio.com

China